The Effectiveness of Vitamin D Supplementation in Patients With End-stage Knee Osteoarthritis

Double-blinded Randomized Controlled Trial Investigating the Effectiveness of Vitamin D Supplementation in Patients With End-stage Knee Osteoarthritis

Osteoarthritis (OA) knee is one of the commonest chronic degenerative conditions. It causes disability in elderlies due to pain and stiffness. The prevalence of radiologic knee osteoarthritis increases in proportion to age, reaching an astounding 64.1% for patients who are over 60 years of age. In 2021, there were over 26,000 patients on the Hospital Authority (HA) waiting list for knee total knee replacement (TKR) and with only 4300 TKRs performed, the nominal waiting time for TKR was almost 89 months.

Low vitamin D can adversely affect cartilage thickness and study suggested that low serum vitamin D is associated with increased radiographic knee OA progression. A systematic review concluded that vitamin D supplements can improve pain and function in patients with knee OA.

Vitamin D has long been recognized for its effect on musculoskeletal health and increasing attention has been focused for its effect on muscle function. Vitamin D have a direct effect on muscle hypertrophy by acting on specific vitamin D receptors (VDRs) on myocytes, and sufficient levels of vitamin D in patients have been found to correlate with an increase in the size, number, and strength of muscle fibres. Vitamin D also seems to exert beneficial effects by its interplay with myokines such as myostatin and irisin.

One study also showed that muscle nuclear VDR was increased by 30% and augmented muscle fibre size by 10% in elderly females (mean age of 78 years) taking vitamin D orally at a rate of 100 µg/day (4000 IU/day) for 4 months.

This will be a double-blinded RCT investigating the effect of vitamin D supplements or knee muscle strength, physical function, pain symptoms and, sarcopenia status. The study will be a follow-up study with assessment at baseline, 3- ,6-and 12-months post vitamin D intervention.

Study Overview

• Status: Recruiting
• Conditions: Knee Osteoarthritis; Vitamin D Deficiency; Sarcopenia
• Intervention / Treatment: Drug: Vitamin D; Drug: Placebo

Detailed Description

Osteoarthritis (OA) knee is one of the common chronic degenerative conditions. It causes disability in elders, leading to pain and stiffness. The prevalence of radiologic knee osteoarthritis and symptomatic knee OA were 37.4% and 12.1% among adults over 60 years of age.

Often, patients with end-stage knee OA often adopt a sedentary lifestyle to avoid joint pain and stiffness. This can have an adverse effect on muscle function both locally around the knees as well as on generalized muscle health. Ageing and inactivity leads to a progressive loss of muscle mass and strength until an abnormally low level, termed "sarcopenia". Sarcopenic elderlies are more likely to develop deterioration of functional outcomes and higher mortality resulting in socioeconomic and healthcare burdens. In contrast, our previous study investigating the prevalence of sarcopenia in end-stage OA showed that 32.8% of severe knee OA patients also suffered sarcopenia, and these patients showed a slower recovery after undergoing TKR.

Vitamin D has long been recognized for its effect on musculoskeletal health, and increasing attention has been focused on its effect on muscle function. Vitamin D directly affects muscle hypertrophy by acting on specific vitamin D receptors (VDRs) in myocytes, and sufficient vitamin D levels in patients have been found to correlate with an increase in the size, number, and strength of muscle fibers. In the Chinese population aged over 65, 30.6% of the population studied presented with vitamin D deficiency (25(OH)D <20 ng/mL). A systematic review concluded that vitamin D supplements can improve pain and function in patients with knee OA. Moreover, patients with end stage OA knees will have more pain, leading to decreased mobility, a higher risk of sarcopenia, and vitamin D insufficiency that would warrant attention.

56 patients with end-stage knee OA scheduled for TKR will be recruited from the Li Ka Shing Orthopaedic Specialist clinic at the Prince of Wales Hospital (PWH) Hong Kong.

Oral and written consents will be obtained from individuals who agree to participate in the study.

The recruitment period will last for 12 months and the whole project period is 2 years in total. Basic demographics, sarcopenia assessment and Outcome Measurement Questionnaires will be carried out. The patients will be advised to avoid taking supplements and keep a record of medication intake throughout the study period.

We will use 4000 IU/day, for 6 months adapted from previous study. All study tablets including the placebo will be manufactured according to Good Manufacturing Practice (GMP) guidelines for quality assurance.

Assessments including quadriceps and hamstring muscle strength, handgrip strength, 6-meter timed walking gait test, chair stand test, muscle mass using Dual Energy X-ray Absorptiometry and questionnaires will be conducted.

• Study Type: Interventional
• Enrollment (Estimated): 56
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Michael Tim-Yun ONG, MSc; Phone Number: 26364171; Email: michael.ong@cuhk.edu.hk
• Study Contact Backup: Name: 26364171 ONG, MSc; Phone Number: 26364171; Email: michael.ong@cuhk.edu.hk

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • Recruiting
    • Prince of Wales Hospital
    • Contact: Michael Tim-Yun Ong; Phone Number: 26364171; Email: michael.ong@cuhk.edu.hk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male and female patients aged over 50 with end-stage knee OA
• Patient are on the waiting list for TKR at Prince of Wales Hospital
• Walk unaided for 6 meters
• Able to comply with the assessments and has given oral and written consent
• Patients with vitamin D insufficiency and deficiency at the baseline measurement (25(OH)D <30 ng/mL)

Exclusion Criteria:

• Patients with connective tissue disorders or myositis condition
• History of any Hip & Knee surgery
• Patients with malnutrition were assessed by Mini-Nutritional assessment.
• Patients with acute immobility (i.e., post-hip fracture or post-acute hospital admission)
• Patient scheduled for TKR within six months
• Patients already taking vitamin D supplements
• Patients with a known contraindication to vitamin D treatment (such as allergy)
• Patients who have renal impairment with glomerular filtration rate (eGFR) < 30 ml/minute

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention group; The intervention group will receive vitamin D supplement for 6 months	Drug: Vitamin D; 4000IU/day vitamin D supplement will be used for 6 months; Other Names: SODX Co., Ltd, Osaka, Japan
Placebo Comparator: Control group; The control group will receive placebo for 6 months	Drug: Placebo; Placebo will be used for 6 months; Other Names: SODX Co., Ltd, Osaka, Japan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quadriceps and hamstring muscle strength assessment	Hand-held dynamometer microFET2 (Hoggan Scientific, Salt Lake City UT, USA) will be used to assess lower limb strength and power. Assessment of isometric muscle strength and power will be performed with the participants in a seated position to assess knee extensors and knee flexors. All tests will involve maximal voluntary isometric contractions. Both limbs will be assessed to record side-to-side difference. Two trials were recorded for each muscle group.	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The 6-meter timed walking test	The 6-meter timed walking test is a well-established test to assess gait speed. However, due to space limitations and the exhaustive nature of the test for patients with OA, the 6-meter test has been documented to be a valid and reliable substitute. Patients will be asked to walk a straight line of 6 meters where the time taken to complete the distance will be measured. (<7.5 seconds is normal).	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
5-time Chair stand test	The chair stand test is a reliable test for assessment for low limb strength in patients. Patients will be asked to sit on a solid chair with arms on shoulders and feet with shoulder width apart. They will be instructed to do 1-2 repetitions to become familiar with the test, and perform as many reputations as they can in 30 seconds.	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Dual Energy X-ray Absorptiometry (DXA)	The radiation for one session (20 minutes) for sarcopenia assessment is less than 25µSv, which is within the safe range. After every DXA scan, two copies will be printed that show the patients' body composition, bone mineral density, fat percentage, body mass index, and most importantly for this study, lean muscle mass.	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)	It is a questionnaire that measures a patient's pain, stiffness and physical function and can be summed up into a score out of 96. A high score indicates a more disabled participant .	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
International Physical Activity Questionnaire (IPAQ)	Assesses and monitors a patient's physical activity and inactivity level. This instrument sums up a patient's activity level per week into three categories, Category 1 Inactivity, category 2 minimally active and category 3 HEPA active	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Nutritional intake questionnaire	Evaluation of habitual dietary intake will be based on retrospective means of assessment for the past twelve months. A Food Frequency Questionnaire (FFQ) previously validated with data obtained in the Hong Kong Adult Dietary Survey in 1995 as described previously will be used(Appendix 7). Daily dietary intake of Vitamin D and calcium will be evaluated by the Food Processor Nutrition Analysis and Fitness software version 7.9 (Esha Research, Salem, USA), with incorporation of local food composition based on food composition table from China	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Handgrip strength	The handgrip dynamometer will be used to test for the patients' handgrip strength. The handgrip dynamometer is an instrument measuring patients' maximum isometric strength of the hand and forearm muscles. The handle of the dynamometer will be adjusted as the finger is at 90 o whilst the dynamometer is being held. The measurement will be repeated three times and the average calculated for the dominant hand (Hand dominance will be determined by observing the patient's writing hand when signing the informed consent).	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Knee Injury and Osteoarthritis Outcome Score (KOOS)	To to evaluate symptoms and function in patients with knee injury and osteoarthritis with five separately scored subscales. Higher scores means better knee function	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Short-Form 36 (SF-36)	36 questions to measure a patient's functional health and well-being from a patient's point of view. It is a reliable and validated measure that summarises the patients' physical and mental health. Higher scores means better quality of life.	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Sunlight exposure questionnaire	The Chinese version of the sunlight exposure questionnaire will be used in this study and has proven to be adequate for measurement of lifetime sunlight exposure among Hong Kong Chinese women. Higher scores means high chance of level vitamin D level.	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Serum myokine evaluation	Blood taking (5 ml) will be performed. The serum will be prepared by centrifugation and kept in a -80º freezer until use. Quantitative analysis for myokines and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities) or enzyme-linked immunosorbent assay (ELISA).	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement
Serum vitamin D assays	Serum 25(OH)Vit-D levels will be measured by a commercial 25(OH) Vitamin D ELISA kit (Abcam ab213966) according to the manufacturer's instruction, providing the quantitative determination of 25(OH) Vitamin D3 and 25(OH) Vitamin D2	Baseline, 3 months, 6 months, 12 months after the the commencement of vitamin D supplement

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Investigators: Principal Investigator: Michael Tim-Yun Ong, Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2024
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): November 30, 2025

Study Registration Dates

• First Submitted: July 31, 2023
• First Submitted That Met QC Criteria: July 31, 2023
• First Posted (Actual): August 8, 2023

Study Record Updates

• Last Update Posted (Actual): March 27, 2024
• Last Update Submitted That Met QC Criteria: March 26, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Vitamin D; Sarcopenia; Knee Osteoarthritis; Muscle atrophy
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Nutrition Disorders; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Avitaminosis; Deficiency Diseases; Malnutrition; Muscular Atrophy; Atrophy; Osteoarthritis; Osteoarthritis, Knee; Vitamin D Deficiency; Sarcopenia; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Vitamin D
• Other Study ID Numbers: 2022.252

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All IPD that underlie results in a publication
• IPD Sharing Time Frame: starting 6 months after publication
• IPD Sharing Access Criteria: Journal reviewer
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No